4SG Stock Overview
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Sol-Gel Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.84 |
| 52 Week High | US$3.36 |
| 52 Week Low | US$0.72 |
| Beta | 1.32 |
| 1 Month Change | -2.31% |
| 3 Month Change | -21.03% |
| 1 Year Change | -72.74% |
| 3 Year Change | -90.56% |
| 5 Year Change | n/a |
| Change since IPO | -90.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4SG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 1.2% |
| 1Y | -72.7% | -28.2% | 2.0% |
Return vs Industry: 4SG underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 4SG underperformed the German Market which returned 2% over the past year.
Price Volatility
| 4SG volatility | |
|---|---|
| 4SG Average Weekly Movement | 15.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4SG's share price has been volatile over the past 3 months.
Volatility Over Time: 4SG's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 36 | Alon Seri-Levy | www.sol-gel.com |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.
Sol-Gel Technologies Ltd. Fundamentals Summary
| 4SG fundamental statistics | |
|---|---|
| Market cap | €23.17m |
| Earnings (TTM) | -€25.46m |
| Revenue (TTM) | €1.45m |
15.9x
P/S Ratio-0.9x
P/E RatioIs 4SG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4SG income statement (TTM) | |
|---|---|
| Revenue | US$1.55m |
| Cost of Revenue | US$23.54m |
| Gross Profit | -US$21.99m |
| Other Expenses | US$5.25m |
| Earnings | -US$27.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | -1,414.86% |
| Net Profit Margin | -1,752.77% |
| Debt/Equity Ratio | 0% |
How did 4SG perform over the long term?
See historical performance and comparison